Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.37 |
| ▸ | THRB | P10828 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1009003 | 0.74 | L3MBTL1 (0.67) | GAATHRBKDM4ERECQLL3MBTL1 | |
| SCHEMBL310102 | 0.71 | — | — | |
| SCHEMBL14208206 | 0.71 | KDM4E (0.42) | GAATHRBKDM4ERECQLL3MBTL1 | |
| SCHEMBL12194202 | 0.69 | — | — | |
| SCHEMBL21997178 | 0.67 | GAA (0.38) | GAATHRBALDH1A1MAPTTDP1 | |
| SCHEMBL14232086 | 0.67 | GAA (0.41) | GAATHRBALDH1A1MAPTTDP1 | |
| SCHEMBL7400810 | 0.66 | ALDH1A1 (0.36) | GAATHRBKDM4ERECQLL3MBTL1 | |
| SCHEMBL6735093 | 0.63 | RECQL (0.35) | RECQLL3MBTL1 | |
| SCHEMBL11205163 | 0.61 | ALDH1A1 (0.51) | GAATHRBKDM4ERECQLL3MBTL1 | |
| SCHEMBL29892531 | 0.61 | ALDH1A1 (0.34) | GAATHRBKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013092463-A1 | 4-AZAINDOLE INHIBITORS OF CRAC | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092444-A1 | DIAZAINDOLE INHIBITORS OF CRAC | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092467-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| US-20130158040-A1 | DIAZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158049-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158066-A1 | 4-AZAINDOLE INHIBITORS OF CRAC | HOFFMANN-LA ROCHE INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013050341-A1 | AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-11 | — | — | WO | disclosed |
| US-20130090334-A1 | AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS | Hoffmann-La Roche Inc (US) | 2013-04-11 | — | — | US | disclosed |
| WO-2013050270-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-11 | — | — | WO | disclosed |
| US-20130090333-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2013-04-11 | — | — | US | disclosed |
| US-20120308588-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| EP-2480529-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| WO-2011036130-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ALAM MUZAFFAR | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071150-A1 | INDOLE DERIVATIVES AS CRAC MODULATORS | ORAI1, RYR2, CACNA1E | GAA 3955/4885THRB 351/4885KDM4E 2583/4885 |
| US-20130158040-A1 | DIAZAINDOLE INHIBITORS OF CRAC | ORAI2, ORAI1, RYR2 | GAA 1908/4885THRB 2079/4885KDM4E 3338/4885 |
| US-20120308588-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | GAA 158/4885THRB 2031/4885KDM4E 2357/4885 |
| US-20130158066-A1 | 4-AZAINDOLE INHIBITORS OF CRAC | ORAI1, CACNA1I, RYR2 | GAA 3122/4885THRB 1868/4885KDM4E 1365/4885 |
| US-20130090333-A1 | BENZOXAZINE DERIVATIVES AS CRAC MODULATORS | RYR2, CACNA1E, RYR1 | GAA 1085/4885THRB 716/4885KDM4E 2904/4885 |
| US-20130090334-A1 | AZABENZOXAZINE DERIVATIVES AS CRAC MODULATORS | ORAI1, CACNA1E, RYR2 | GAA 1973/4885THRB 554/4885KDM4E 1369/4885 |
| US-20130158049-A1 | 7-AZAINDOLE INHIBITORS OF CRAC | ORAI1, CACNA1I, RYR2 | GAA 2667/4885THRB 2019/4885KDM4E 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.